Form 4: ADMA Biologics CEO Reports RSU Tax Withholding

ADMA Biologics President and CEO Adam S. Grossman reported the withholding of 54,858 shares of common stock to cover tax obligations upon the vesting of restricted stock units.

Summary

• Adam S. Grossman, President and CEO of ADMA Biologics, reported a transaction involving 54,858 shares of common stock.
• The transaction, dated February 26, 2026, was a withholding by the Issuer to satisfy mandatory tax requirements upon the vesting of restricted stock units (RSUs).
• This was not an open market sale of securities.
• The shares were withheld at a price of $15.18 per share.
• Following this transaction, Mr. Grossman directly beneficially owns 2,204,728 shares of common stock, which includes vested shares and various tranches of unvested RSUs.
• He also indirectly beneficially owns 1,143,426 shares through Areth, LLC, and 580,957 shares through Hariden, LLC, where he is a control person or managing member, respectively.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event, as the vesting of RSUs indicates the achievement of performance or time-based milestones and the CEO's continued commitment to the company, despite the associated tax withholding.

Positives

• The vesting of restricted stock units indicates continued service and performance by the President and CEO, Adam S. Grossman.
• The transaction is a routine tax withholding event, not a discretionary sale by the insider, suggesting continued commitment to the company.

Negatives

• No inherent negatives are indicated by this routine tax withholding transaction.

Future Outlook

The filing details several tranches of unvested Restricted Stock Units (RSUs) granted to Adam S. Grossman, with vesting schedules extending over four years from their respective grant dates (February 9, 2026; February 19, 2025; February 26, 2024; March 6, 2023; and March 7, 2022). These RSUs will settle into common stock upon vesting, subject to his continued service, indicating a long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that the tax withholding upon RSU vesting is a standard and routine event in executive compensation across various industries, particularly in biotechnology and pharmaceuticals. This mechanism allows executives to cover tax liabilities incurred when equity awards vest, without requiring them to sell shares on the open market, thereby often signaling continued commitment to the company's long-term performance.

Related Party Transactions

• Adam S. Grossman indirectly owns 1,143,426 shares through Areth, LLC, where he is a control person.
• Adam S. Grossman indirectly owns 580,957 shares through Hariden, LLC, where he is the managing member.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax event, but it confirms the CEO's continued equity stake and long-term incentive alignment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued vesting of various tranches of Restricted Stock Units (RSUs) on their respective annual anniversaries over four years, subject to Adam S. Grossman's continued service.

Key Dates

Keywords

ADMA Biologics, ADMA, Adam S. Grossman, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation, Beneficial Ownership